Cargando…

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Peng, Yurong, Li, Zhuo, Fu, Yucheng, Pan, Yue, Zeng, Yue, Liu, Junqi, Xiao, Chaoyue, Zhang, Yingzhe, Su, Yahui, Li, Guoqing, Wu, Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092814/ https://www.ncbi.nlm.nih.gov/pubmed/37064096 http://dx.doi.org/10.3389/fonc.2023.1163376

Ejemplares similares

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Tertiary Lymphoid Structures: A Potential Biomarker for Anti-Cancer Therapy
por: Zou, Ji’an, et al.
Publicado: (2022)

Perspectives on Immunotherapy of Metastatic Colorectal Cancer
por: Dai, Yongjiu, et al.
Publicado: (2021)

Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
por: Ni, Yunfeng, et al.
Publicado: (2023)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
por: Pan, Yue, et al.
Publicado: (2022)

Cancer immunotherapy strategies that target the cGAS-STING pathway
por: Tian, Zhuoying, et al.
Publicado: (2022)

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas
por: Pan, Changqing, et al.
Publicado: (2021)

Corrigendum: CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
por: Song, Yue, et al.
Publicado: (2021)

Corrigendum: Molecular Mechanism and Approach in Progression of Meningioma
por: Shao, Zhiwei, et al.
Publicado: (2020)

Research progress of nanovaccine in anti-tumor immunotherapy
por: Yao, Min, et al.
Publicado: (2023)

Corrigendum: The Emerging Role of the c-MET-HGF Axis in Non-small Cell Lung Cancer Tumor Immunology and Immunotherapy
por: Titmarsh, Helen F., et al.
Publicado: (2020)

Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives
por: Zhang, Shuang, et al.
Publicado: (2023)

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
por: Xu, Yanjun, et al.
Publicado: (2021)

Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
por: Wu, Xinyu, et al.
Publicado: (2023)

The Application of CRISPR/Cas9 Technology for Cancer Immunotherapy: Current Status and Problems
por: Wang, Luyao, et al.
Publicado: (2022)

Research Progress on the Microenvironment and Immunotherapy of Advanced Non-Small Cell Lung Cancer With Liver Metastases
por: Fang, Yujia, et al.
Publicado: (2022)

Immunotherapy progress and clinical strategy of unresectable locally advanced non-small cell lung cancer
por: Zhang, Xiaofei, et al.
Publicado: (2023)

Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective
por: Li, Ying, et al.
Publicado: (2023)

Corrigendum: TFEB Promotes Prostate Cancer Progression via Regulating ABCA2-Dependent Lysosomal Biogenesis
por: Zhu, Xuejin, et al.
Publicado: (2021)

Corrigendum: Application of and Clinical Research on Enhanced Recovery After Surgery in Perioperative Care of Patients With Supratentorial Tumors
por: Wu, Jingmi, et al.
Publicado: (2022)

Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota
por: Wei, Yibing, et al.
Publicado: (2023)

Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma
por: Xie, Shuqi, et al.
Publicado: (2023)

Progression in immunotherapy for advanced prostate cancer
por: Liang, Hao, et al.
Publicado: (2023)

TAM-targeted reeducation for enhanced cancer immunotherapy: Mechanism and recent progress
por: Shen, Xinyuan, et al.
Publicado: (2022)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Editorial: Perioperative management and cancer outcome
por: Tao, Yiying, et al.
Publicado: (2023)

Research Progress of Anti-PD-1/PD-L1 Immunotherapy Related Mechanisms and Predictive Biomarkers in NSCLC
por: Bie, Fenglong, et al.
Publicado: (2022)

Corrigendum: Biomarking and induction of apoptosis in ovarian cancer using bifunctional polyethyleneimine-caged platinum nanoclusters
por: Zhang, Mengjun, et al.
Publicado: (2022)

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis
por: Yang, Yin, et al.
Publicado: (2022)

Corrigendum: Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy
por: Zhao, Ni, et al.
Publicado: (2022)

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives
por: Alberti, Andrea, et al.
Publicado: (2022)

Corrigendum: Loss of TARBP2 Drives the Progression of Hepatocellular Carcinoma via miR-145-SERPINE1 Axis
por: Li, Li-Man, et al.
Publicado: (2021)

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
por: Wang, Yunzhen, et al.
Publicado: (2023)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2021)

Corrigendum: DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression
por: Xu, Kun, et al.
Publicado: (2023)

Impact of interaction networks of B cells with other cells on tumorigenesis, progression and response to immunotherapy of renal cell carcinoma: A review
por: Wang, Yu-qi, et al.
Publicado: (2022)

Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy
por: Xie, Dong, et al.
Publicado: (2022)

Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy
por: Zhang, Wenxiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qsrhb7bmv91l091t2nigeoh8ni